New updates have been reported about Insilico Medicine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insilico Medicine has signed a major global R&D and licensing agreement with Eli Lilly that puts its AI-driven drug discovery platform at the center of a multiyear pipeline-building effort across several therapeutic areas. Lilly receives an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral drug candidates that Insilico has advanced into preclinical development for specified indications, while the two companies will jointly run multiple discovery programs on targets chosen by Lilly using Insilico’s Pharma.AI technology.
Financially, Insilico is set to receive an upfront payment of $115 million, with total potential development, regulatory, and commercial milestones of about $2.75 billion plus tiered royalties on eventual product sales, creating a significant non-dilutive capital source following its December 2025 listing on the Main Board of the Hong Kong Stock Exchange under code 03696.HK. Strategically, the collaboration validates Insilico’s end-to-end generative AI approach to drug discovery, expands its reach into Lilly-led disease areas with high unmet need, and could accelerate AI-derived assets in fibrosis, oncology, immunology, pain, and metabolic disorders, while also strengthening its position as a platform partner of choice for large pharma and reinforcing the commercial value of its broader AI and automation stack beyond biopharma.